Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of Ambroxol in prodromal and mild dementia with Lewy bodies
2019-002855-41Phase 2Active
- Sponsor
- Helse Fonna
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) and mild cognitive impairment with Lewy bodies (MCI-LB) comparing Ambroxol (Mucosolvan) arm with Placebo arm (2 arms). Primary endpoints: Cognitive outcomes (MMSE and cognitive test battery), Neuropsychiatric symptoms and 1 more. Started Apr 2020; status: active.
02
Drugs
ambroxol
03
Conditions
dementia with Lewy bodies (DLB)mild cognitive impairment with Lewy bodies (MCI-LB)
Beyond the preview
Go deeper on 2019-002855-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002855-41.